Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering

Journal of the American Society of Nephrology

Volumn 16, Issue 12, 2005, Pages 3631-3641

  Izuhara, Yuko ^a   Nangaku, Masaomi ^b   Inagi, Reiko ^a   Tominaga, Naoto ^a   Aizawa, Toru ^a   Kurokawa, Kiyoshi ^a   Van Ypersele De Strihou, Charles ^c   Miyata, Toshio ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 3 (2 HYDROXYPHENYL)ALANINE; ALPRENOLOL; AMINOGUANIDINE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARBOXYMETHYLCELLULOSE; CARTEOLOL; FELODIPINE; HYDROXYL RADICAL; IRBESARTAN; LOSARTAN; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; OLMESARTAN; PENTOSIDINE; PYRIDOXAMINE; TELMISARTAN; TRANSITION ELEMENT; UNINDEXED DRUG; VALSARTAN; ANGIOTENSIN RECEPTOR; ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; LYSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CELL INFILTRATION; CLINICAL STUDY; CONTROLLED STUDY; DRUG MECHANISM; FENTON REACTION; HUMAN; HYPERTENSION; KIDNEY INJURY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; ANALYSIS OF VARIANCE; ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY; METABOLISM; NEEDLE BIOPSY; NONPARAMETRIC TEST; PATHOLOGY; RAT; RENOVASCULAR HYPERTENSION; SENSITIVITY AND SPECIFICITY; SPONTANEOUSLY HYPERTENSIVE RAT;

ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARGININE; BIOPSY, NEEDLE; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; HYPERTENSION, RENAL; IMMUNOHISTOCHEMISTRY; KIDNEY; LYSINE; MALE; RATS; RATS, INBRED SHR; RECEPTORS, ANGIOTENSIN; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 33645308317     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005050522     Document Type: Article

References (49)

1. Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145-1151, 2002
2. Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341: 1127-1133, 1999
3. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996
4. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
6. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
7. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
8. Viberti G, Wheeldon NM; Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106: 672-678, 2002
9. Baba S; the J-MIND Study group: Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54: 191-201, 2001
10. Schrier RW, Estacio Esler, Mehler P: Effect of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61: 1086-1097, 2002
11. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 13: 2478-2487, 2002
12. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478, 1993
13. Horie K, Miyata T, Yasuda T, Takeda A, Yasuda Y, Maeda K, Sobue G, Kurokawa K: Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem Biophys Res Commun 236: 327-332, 1997
14. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55: 389-399, 1999
15. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51: 3274-3282, 2002
16. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S: Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 17: 23S-30S, 2004
17. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM: Identification of pentosidine as a native structure for advanced glycation end products in beta2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci U S A 93: 2353-2358, 1996
18. Huggins TG, Wells-Knecht MC, Detorie NA, Baynes JW, Thorpe SR: Formation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. J Biol Chem 268: 12341-12347, 1993
19. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, van Ypersele de Strihou C, Kurokawa K: Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14: 1212-1222, 2003
20. Perls M: Prussian blue technique/Berlinerblau Reaktion. In: Romeis: Mikroskopische Technik, Vol. 1, 17th Ed., edited by Bock P, Munich, Urban and Schwarzenberg, 1989, p 564
21. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, Kurokawa K, Fujita T, Nangaku M: Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 15: 1277-1288, 2004
22. Monnier VM: Transition metals redox: Reviving an old plot for diabetic vascular disease. J Clin Invest 107: 799-801, 2001
23. Floege J, Alpers CE, Sage EH, Pritzl P, Gordon K, Johnson RJ, Couser WG: Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal changes. Lab Invest 67: 486-497, 1992
24. Eddy AA: Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 135: 719-733, 1989
25. Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzi P, Gordon K, Gown AM: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 87: 847-858, 1991
26. Maines MD: Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 2: 2557-2568, 1988
27. Morimoto K, Ohta K, Yachie A, Yang Y, Shimizu M, Goto C, Toma T, Kasahara Y, Yokoyama H, Miyata T, Seki H, Koizumi S: Cytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseases. Kidney Int 60: 1858-1866, 2001
28. Okamura N, Babior BM, Mayo LA, Peveri P, Smith RM, Curnutte JT: The p67-phox cytosolic peptide of the respiratory burst oxidase from human neutrophils. Functional aspects. J Clin Invest 85: 1583-1587, 1990
29. Patrick DH, Hansen CT, Canary JJ, Werner RM, Carswell N: Insulin-independent diabetes mellitus (type II) spontaneous hypertensive/NIH corpulent rat. Am J Pathol 123: 398-400, 1986
30. Zhou XJ, Laszaik Z, Wang XQ, Silva FG, Vaziri ND: Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 80: 1905-1914, 2000
31. Paller MS, Hedlund BE: Role of iron in postischemic renal injury in the rat. Kidney Int 34: 474-480, 1988
32. Alfrey AC, Froment DH, Hammond WS: Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 36: 753-759, 1989
33. Nankivell BJ, Boadle RA, Harris DC: Iron accumulation in human chronic renal diseases. Am J Kidney Dis 20: 580-584, 1992
34. Zhou XJ, Vaziri ND, Pandian D, Wang ZQ, Mizowiecki M, Liao SY, Oveisi F: Urinary concentrating defect in experimental hemochromatosis. J Am Soc Nephrol 7: 128-134, 1996
35. Ishizaka N, Aizawa T, Yamazaki L, Usui S, Mori I, Kurokawa K, Tang SS, Ingelfinger JR, Ohno M, Nagai R: Abnormal iron deposition renal cells in the rat with chronic angiotensin II administration. Lab Invest 82: 87-96, 2002
36. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, Choi AM: Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272: 5375-5381, 1997
37. Nath KA, Vercellotti GM, Grande JP, Miyoshi H, Paya CV, Manivel JC, Haggard JJ, Croatt AJ, Payne WD, Alam J: Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1. Kidney Int 59: 106-117, 2001
38. Aizawa T, Ishizaka N, Taguchi J, Nagai R, Mori I, Tang SS, Ingelfinger JR, Ohno M: Heme oxygenase-1 is upregulated in kidney of angiotensin II-induced hypertensive rat: Possible role in renoprotection. Hypertension 35: 800-806, 2000
39. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN: Bilirubin is an antioxidant of possible physiological importance. Science 235: 1043-1046, 1987
40. Ferris CD, Jaffrey SR, Sawa A, Takahashi M, Brady SD, Barrow RK, Tysoe SA, Wolosker H, Baranano DE, Dore S, Poss KD, Snyder SH: Heme oxygenase-1 prevents cell death by regulating cellular iron. Nat Cell Biol 1: 152-157, 1999
41. Mazzali M, Jefferson JA, Ni Z, Vaziri ND, Johnson RJ: Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Int 636: 2088-2093, 2003
42. Ries M, Basseau F, Tyndal B, Jones R, Deminiere C, Catargi B, Combe C, Moonen CW, Grenier N: Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imag 1: 104-113, 2003
43. Tanaka T, Miyata T, Inagi R, Fujita T, Nangaku M: Hypoxia in renal disease with proteinuria and/or glomerular hypertension. Am J Pathol 165: 1979-1992, 2004
44. Norman JT, Stidwill R, Singer M, Fine LG: Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel, potentially renoprotective action. Nephron Physiol 94: 39-46, 2003
45. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, Kurokawa K, Fujita T, Nangaku M: Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 15: 1277-1288, 2004
46. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T: Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42: 31-38, 2003
47. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897, 1994
48. Miyata T, Hori O, Zhang JH, Yan SD, Ferran L, Iida Y, Schmidt AM: The receptor for advanced glycation endproducts (RAGE) is a central mediator of the interaction of AGE-beta2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98: 1088-1094, 1996
49. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M: Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 65: 871-880, 2004